Table of Contents:

1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of the Study
3.3 Research Objective
3.4 Assumptions & Limitations
3.4.1 Assumptions
3.4.2 Limitations
3.5 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Rising prevalence of autoimmune diseases
5.2.2 Increasing research and development related to plasma-derived medicines
5.2.3 Increasing awareness about Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.3 Restraints
5.3.1 Side-effects associated with the Intravenous Immunoglobulin (IVIG) treatment
5.3.2 High cost of the IVIG treatment
5.4 Opportunity
5.4.1 Advancements in the treatment
5.5 Clinical Trials Data
6 Market Factor Analysis
6.1 Porter's Five Forces Model
6.1.1 Bargaining Power of Suppliers
6.1.2 Bargaining Power of Buyers
6.1.3 Threat of New Entrants
6.1.4 Threat of Substitutes
6.1.5 Intense Rivalry
6.2 Supply Chain Analysis
6.2.1 R&D and Designing
6.2.2 Manufacturing
6.2.3 Distribution & Sales
6.2.4 Post-Sales Monitoring
7 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
7.1 Introduction
7.2 Treatment
7.3 Diagnosis
8 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
8.1 Introduction
8.2 Intravenous
8.3 Oral
9 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
9.1 Introduction
9.2 Hospitals
9.3 Specialty Neurological Clinics
9.4 Research & Academic Laboratories
10 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 U.K
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 Middle East and Africa
10.5.1 Middle East
10.5.2 Africa
11 Competitive Landscape
11.1 Company Market Share Analysis
11.2 Introduction
12 Company Profiles
12.1 Grifols
12.1.1 Company Overview
12.1.2 Financial Overview
12.1.3 Products/Services Offered
12.1.4 SWOT Analysis
12.1.5 Key Developments
12.1.6 Key strategy
12.2 Shire
12.2.1 Company Overview
12.2.2 Financial Overview
12.2.3 Products/Services Offered
12.2.4 SWOT Analysis
12.2.5 Key Developments
12.2.6 Key strategy
12.3 Baxter
12.3.1 Company Overview
12.3.2 Company Overview
12.3.3 Products/Services Offered
12.3.4 SWOT Analysis
12.3.5 Key Developments
12.3.6 Key strategy
12.4 Pfizer, Inc.
12.4.1 Company Overview
12.4.2 Financial Overview
12.4.3 Products/Services Offered
12.4.4 SWOT Analysis
12.4.5 Key Developments
12.4.6 Key Strategy
12.5 CSL Behring
12.5.1 Company Overview
12.5.2 Financial Overview
12.5.3 Products/Services Offered
12.5.4 SWOT Analysis
12.5.5 Key Developments
12.5.6 Key Strategy
12.6 Kedrion S.p.A
12.6.1 Company Overview
12.6.2 Financial Overview
12.6.3 Products/Services Offered
12.6.4 SWOT Analysis
12.6.5 Key Development
12.6.6 Key Strategy
12.7 Octapharma
12.7.1 Company Overview
12.7.2 Financial Overview
12.7.3 Products/Services Offered
12.7.4 SWOT Analysis
12.7.5 Key Development
12.7.6 Key Strategy
12.8 Momenta Pharmaceuticals
12.8.1 Company Overview
12.8.2 Financial Overview
12.8.3 Products/Services Offered
12.8.4 SWOT Analysis
12.8.5 Key Development
12.8.6 Key Strategy
12.9 Teijin Pharma Limited
12.9.1 Company Overview
12.9.2 Financial Overview
12.9.3 Products/Services Offered
12.9.4 SWOT Analysis
12.9.5 Key Developments
12.9.6 Key strategy
12.1 Mitsubishi Tanabe Pharma Corporation
12.10.1 Company Overview
12.10.2 Financial Overview
12.10.3 Products/Services Offered
12.10.4 SWOT Analysis
12.10.5 Key Developments
12.11 Bio Products Laboratory Ltd.
12.11.1 Company Overview
12.11.2 Financial Overview
12.11.3 Products/Services Offered
12.11.4 SWOT Analysis
12.11.5 Key Developments
12.11.6 Key strategy
13 Appendix
13.1 Discussion Blue Print